

Supplementary Table 1. Prescription status of triple combination of OHAs in study population at baseline

| Triple combinations (<i>n</i> =357) | | | No. (%) |
|--------------------------------------|-------------------------|---------------------------------|------------|
| Metformin | Sulfonylurea or glinide | DPP4 inhibitor | 239 (66.9) |
| | | Thiazolidinedione | 39 (10.9) |
| | | α -Glucosidase inhibitor | 16 (4.5) |
| | | SGLT2 inhibitor | 13 (3.6) |
| | DPP4 inhibitor | Thiazolidinedione | 29 (8.1) |
| | | SGLT2 inhibitor | 9 (2.5) |
| | | Thiazolidinedione | 2 (0.6) |
| Sulfonylurea or glinide | Thiazolidinedione | DPP4 inhibitor | 6 (1.7) |
| | | SGLT2 inhibitor | 1 (0.3) |
| | DPP4 inhibitor | α -Glucosidase inhibitor | 2 (0.6) |
| | | SGLT2 inhibitor | 1 (0.3) |

OHA, oral hypoglycemic agent; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2.